Literature DB >> 18483187

Whole-tumor perfusion CT parameters and glucose metabolism measurements in head and neck squamous cell carcinomas: a pilot study using combined positron-emission tomography/CT imaging.

S Bisdas1, K Spicer, Z Rumboldt.   

Abstract

BACKGROUND AND
PURPOSE: Previous (separately performed) perfusion CT (PCT) and PET studies have been inconclusive regarding the correlation of functional tumor characteristics. The purpose of this study was to perform dual assessment of head and neck squamous cell carcinomas (SCCAs) to examine the relationship between perfusion measurements derived from PCT and glucose standardized uptake values (SUV).
MATERIALS AND METHODS: We prospectively evaluated 15 primary and recurrent SCCAs using combined positron-emission tomography (PET) and CT of the head and neck. SUV(mean), SUV(max), blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability (PS) values were calculated with use of manually drawn regions of interest (ROIs) over the lesions and the healthy muscle tissue. Parametric comparison test, correlation coefficients, and regression analysis were performed.
RESULTS: The mean (+/- SD) SUV(mean), SUV(max), BF, BV, MTT, and PS values in the tumor tissue were 6.26 (+/- 1.48), 15.25 (+/- 3.81), 91.50 (+/- 24.69), 5.08 (+/- 1.17), 7.51 (+/- 2.24), and 23.08 (+/- 8.77), respectively. All PET/CT and PCT parameters of muscle versus tumor tissue were statistically different (.0001 < P < .001). There were significant correlations between BF and SUV(max) as well as SUV(mean) (r = 0.57; P = .02 and r = 0.63; P = .011, respectively) in the tumors. Significant correlation was also found between PS and SUV(mean) (r = 0.53; P = .04) in the tumors. Regression analysis showed: SUV(max) = 0.09 x BF + 7.2 (R(2) = 0.33; P = .02), SUV(mean) = 0.05 x BF + 2.22 (R(2) = 0.45; P = .011), and SUV(mean) = 0.05 x PS + 5.36 (R(2) = 0.35; P = .04). The tumor to nontumor (muscle) SUV(mean) and SUV(max) ratio was 9.45 (+/- 3.55) and 17.58 (+/- 4.32), respectively. BF-ratio SUV(mean) and BF-ratio SUV(max) showed significant correlations (r = 0.64; P = .01 and r = 0.53; P = .04, respectively). Regression analysis showed ratio SUV(mean) = 0.14 x BF-3.48 (R(2) = 0.42; P = .01) and ratio SUV(max) = 0.14 x BF + 4.51 (R(2) = 0.29; P = .04).
CONCLUSION: Tissue perfusion-metabolic coupling is evident in head and neck SCCAs and may provide additional diagnostic information in patients undergoing PET/CT studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483187      PMCID: PMC8119162          DOI: 10.3174/ajnr.A1111

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Reproducibility, repeatability, correlation and measurement error.

Authors:  S Halligan
Journal:  Br J Radiol       Date:  2002-02       Impact factor: 3.039

2.  Perfusion CT for head and neck tumors: pilot study.

Authors:  Zoran Rumboldt; Riyadh Al-Okaili; John P Deveikis
Journal:  AJNR Am J Neuroradiol       Date:  2005-05       Impact factor: 3.825

3.  FDG-PET prediction of head and neck squamous cell cancer outcomes.

Authors:  David L Schwartz; Joseph Rajendran; Bevan Yueh; Marc D Coltrera; Michael Leblanc; Janet Eary; Kenneth Krohn
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-12

4.  Non-invasive tumour perfusion measurement by dynamic CT: preliminary results.

Authors:  R Hermans; P Lambin; W Van den Bogaert; K Haustermans; A Van der Goten; A L Baert
Journal:  Radiother Oncol       Date:  1997-08       Impact factor: 6.280

5.  Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism.

Authors:  Ukihide Tateishi; Hiroshi Nishihara; Eriko Tsukamoto; Toshiaki Morikawa; Nagara Tamaki; Kazuo Miyasaka
Journal:  J Comput Assist Tomogr       Date:  2002 Mar-Apr       Impact factor: 1.826

6.  Biological correlates of FDG uptake in non-small cell lung cancer.

Authors:  Lioe-Fee de Geus-Oei; J Han J M van Krieken; Riena P Aliredjo; Paul F M Krabbe; Cathelijne Frielink; Ad F T Verhagen; Otto C Boerman; Wim J G Oyen
Journal:  Lung Cancer       Date:  2006-10-13       Impact factor: 5.705

7.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.

Authors:  H Vesselle; R A Schmidt; J M Pugsley; M Li; S G Kohlmyer; E Vallires; D E Wood
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

8.  Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.

Authors:  Michael Sørensen; Michael R Horsman; Paul Cumming; Ole Lajord Munk; Susanne Keiding
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

9.  Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.

Authors:  Joseph G Rajendran; David L Schwartz; Janet O'Sullivan; Lanell M Peterson; Patrick Ng; Jeffrey Scharnhorst; John R Grierson; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

10.  Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.

Authors:  Joseph G Rajendran; David A Mankoff; Finbarr O'Sullivan; Lanell M Peterson; David L Schwartz; Ernest U Conrad; Alexander M Spence; Mark Muzi; D Greg Farwell; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

View more
  27 in total

1.  64-row MDCT perfusion of head and neck squamous cell carcinoma: technical feasibility and quantitative analysis of perfusion parameters.

Authors:  Lorenzo Faggioni; Emanuele Neri; Francesca Cerri; Eugenia Picano; Veronica Seccia; Luca Muscatello; Stefano Sellari Franceschini; Carlo Bartolozzi
Journal:  Eur Radiol       Date:  2010-07-23       Impact factor: 5.315

2.  Combined PET/CT-perfusion in patients with head and neck cancers.

Authors:  Patrick Veit-Haibach; Daniel Schmid; Klaus Strobel; Jan D Soyka; Niklaus G Schaefer; Stephan K Haerle; Gerhard Huber; Gabriele Studer; Burkhardt Seifert; Thomas F Hany
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

3.  Prediction of locoregional control in head and neck squamous cell carcinoma with serial CT perfusion during radiotherapy.

Authors:  M T Truong; N Saito; A Ozonoff; J Wang; R Lee; M M Qureshi; S Jalisi; O Sakai
Journal:  AJNR Am J Neuroradiol       Date:  2011-07-14       Impact factor: 3.825

Review 4.  Hybrid PET-dynamic CECT in the management of breast cancer.

Authors:  Rakesh Kumar; Chandan Jyoti Das
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

5.  Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.

Authors:  Michael A Fischer; Bart Vrugt; Hatem Alkadhi; Dieter Hahnloser; Thomas F Hany; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-24       Impact factor: 9.236

Review 6.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

7.  An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer.

Authors:  Sotirios Bisdas; Oliver Seitz; Markus Middendorp; Nicole Chambron-Pinho; Theodosios Bisdas; Thomas J Vogl; Renate Hammerstingl; Ulrike Ernemann; Martin G Mack
Journal:  Eur Radiol       Date:  2010-05-05       Impact factor: 5.315

8.  Brain perfusion CT compared with ¹⁵O-H₂O PET in patients with primary brain tumours.

Authors:  Julie Marie Grüner; Rune Paamand; Michael Kosteljanetz; Helle Broholm; Liselotte Højgaard; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-27       Impact factor: 9.236

9.  Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.

Authors:  An-Na Tong; Shao-Rong Han; Peng Yan; Hai Gong; Hui Zhao; Hui Yao; Yan-Ming Wang
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

10.  Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target.

Authors:  Paolo Farace; Daniela D'Ambrosio; Flavia Merigo; Mirco Galiè; Cristina Nanni; Antonello Spinelli; Stefano Fanti; Anna Degrassi; Andrea Sbarbati; Domenico Rubello; Pasquina Marzola
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.